Fundz

YS Biopharma Appoints Dave Chenn as Interim CEO and Hui Shao as Co-CEO and CBO

PRIVATEMay 07, 2024

Position

Chief Executive Officer

Company

YS Biopharma

Hui Shao
hui.shao@yishengbio.com
GaithersburgManufacturingBiotechnologyHealth CareTherapeuticsPharmaceuticalBiopharmaBiotechnology Research

Description

YS Biopharma announced the appointment of Mr. Dave Chenn as the Interim Chief Executive Officer of the Company and the appointment of Dr. Hui Shao, the then-current Chief Executive Officer of the Company, as the Co-Chief Executive Officer and Chief Business Officer of the Company, each effective on May 2, 2024.

Other recent leadership changes in Therapeutics and Pharmaceutical

Executive moves at companies in the same sectors within 45 days, from Fundz verified event records.

Who to call at YS Biopharma, and when

A new leader at YS Biopharma brings new priorities and often new vendors. The first weeks are when they listen.

  • An alert the day YS Biopharma raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at YS Biopharma, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at YS Biopharma. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

YS Biopharma

Location

Gaithersburg, Maryland, United States

About

YS Biopharma is a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer. The company is focused on making a positive impact on public health worldwide.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment YS Biopharma changes its leadership, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

Dave
Likely contact at this company
••••••••@••••••••

See Dave's verified email →

Create an account to reveal verified emails
Predictive Intelligence
Strategic

ML-powered predictions for YS Biopharma's next move

Learn about Strategic plan

YS Biopharma changed its leadership. Fundz had it the day it was filed, with the decision-maker at the company attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.